| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
|
Lancet
|
2012
|
7.31
|
|
2
|
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
|
J Clin Oncol
|
2010
|
5.01
|
|
3
|
Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.
|
J Clin Oncol
|
2007
|
3.70
|
|
4
|
Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02.
|
J Clin Oncol
|
2013
|
1.96
|
|
5
|
Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors.
|
Support Care Cancer
|
2013
|
1.42
|
|
6
|
Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC.
|
J Neurooncol
|
2008
|
1.42
|
|
7
|
Metaplastic breast cancer: clinicopathological features and its prognosis.
|
J Clin Pathol
|
2012
|
1.13
|
|
8
|
Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer.
|
Cancer
|
2007
|
1.05
|
|
9
|
A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results.
|
Lung Cancer
|
2010
|
0.99
|
|
10
|
A single institutional experience of surgically resected thymic epithelial tumors over 10 years: clinical outcomes and clinicopathologic features.
|
Oncol Rep
|
2008
|
0.95
|
|
11
|
A feasibility study of adenosine triphosphate-based chemotherapy response assay (ATP-CRA) as a chemosensitivity test for lung cancer.
|
Cancer Res Treat
|
2005
|
0.95
|
|
12
|
Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen.
|
J Cancer Res Clin Oncol
|
2011
|
0.89
|
|
13
|
Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer.
|
Breast Cancer Res Treat
|
2005
|
0.89
|
|
14
|
A case of paraneoplastic nephrotic syndrome in a patient with ovarian carcinoma.
|
Yonsei Med J
|
2003
|
0.88
|
|
15
|
Prediction of outcomes for patients with brain parenchymal metastases from breast cancer (BC): a new BC-specific prognostic model and a nomogram.
|
Neuro Oncol
|
2012
|
0.82
|
|
16
|
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02).
|
Breast Cancer Res Treat
|
2015
|
0.82
|
|
17
|
Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients.
|
BMC Cancer
|
2008
|
0.82
|
|
18
|
Do Recent Advances in Diagnostic and Therapeutic Procedures Negate the Benefit of Postmastectomy Radiotherapy in N1 Patients With a Low Risk of Locoregional Recurrence?
|
Medicine (Baltimore)
|
2015
|
0.80
|
|
19
|
Multi-disciplinary treatment of a rare pelvic cavity ependymoma.
|
Yonsei Med J
|
2007
|
0.79
|
|
20
|
The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC.
|
Lung Cancer
|
2007
|
0.79
|
|
21
|
Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.
|
Cancer Chemother Pharmacol
|
2007
|
0.79
|
|
22
|
Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial.
|
Lung Cancer
|
2010
|
0.79
|
|
23
|
Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer.
|
Head Neck
|
2010
|
0.78
|
|
24
|
Development of a Conditional Replication Competent Adenovirus, Controlled by the Human Telomerase Promoter (hTERT).
|
Cancer Res Treat
|
2003
|
0.76
|
|
25
|
Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided versus empirical chemotherapy in unresectable non-small cell lung cancer.
|
Anticancer Res
|
2009
|
0.76
|
|
26
|
Increased Cytopathic Effect of Replicating Adenovirus Expressing Adenovirus Death Protein.
|
Cancer Res Treat
|
2003
|
0.75
|
|
27
|
A pilot study of trans-arterial injection of 166Holmium-Chitosan complex for treatment of small hepatocellular carcinoma.
|
Yonsei Med J
|
2005
|
0.75
|
|
28
|
Phase II Study of Topotecan and Etoposide as Second-line Treatment in Chemotherapy-refractory Small-cell Lung Cancer.
|
Cancer Res Treat
|
2002
|
0.75
|
|
29
|
Infusional 5-Fluorouracil, Leucovorin and Docetaxel in Advanced Gastric Cancer.
|
Cancer Res Treat
|
2003
|
0.75
|
|
30
|
Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
|
Cancer Chemother Pharmacol
|
2009
|
0.75
|
|
31
|
The Effect of ZD 1839 (Iressa(R)) in the Treatment of Refractory Non Small Cell Lung Cancer.
|
Cancer Res Treat
|
2003
|
0.75
|
|
32
|
Paclitaxel and Cisplatin Combination Chemotherapy in Pretreated Breast Cancer.
|
Cancer Res Treat
|
2003
|
0.75
|
|
33
|
Phase II Study of Gemcitabine and Vinorelbine as Second-Line Chemotherapy in Non-Small Cell Lung Cancer.
|
Cancer Res Treat
|
2003
|
0.75
|
|
34
|
A Phase II Study of Gemcitabine Monotherapy in Breast Cancer Patients Refractory to Anthracycline and Taxane.
|
Cancer Res Treat
|
2002
|
0.75
|